Navigation Links
U.S. Supreme Court Invalidates Patents on Breast and Ovarian Cancer Genes
Date:6/13/2013

Chicago, IL (PRWEB) June 13, 2013

The U.S. Supreme Court today invalidated patents on two genes associated with hereditary breast and ovarian cancer in response to a lawsuit filed by the American Civil Liberties Union (ACLU), which includes the American Society for Clinical Pathology (ASCP) and several other medical professional associations, on behalf of researchers, genetic counselors, patients, and breast cancer and women’s health groups that has far-reaching implications for pathology, laboratory medicine, and patients.

“Isolated DNA is a product and law of nature, not an invention, so it is not open to patent protection,” said Steve Kroft, MD, FASCP, president-elect of ASCP. “Gene patents hinder advances in patient care and make the process slower and more expensive for women to find out if they have certain gene mutations that could adversely affect their health.”

The patents allowed a Utah company, Myriad Genetics, to control access to the genes, known as BRCA1 and BRCA2, which gave them the right to limit others from doing research or diagnostic testing of the genes, which can be crucial for individuals making important medical decisions. By enforcing its patent for the testing of patients for BRCA1 and BRCA2 gene alterations for many years, Myriad Genetics has prevented other laboratories from developing tests for these mutations and limited research on these gene alterations that could lead to advances in diagnosis and treatment for patients.

“I know the costs of these tests will be considerably lower without patent protection, allowing more women at risk to be tested,” said Ossama Tawfik, MD, PhD, FASCP, a member of the ASCP Fellow Council and an expert in breast cancer pathology at the University of Kansas Medical Center.

The Court’s unanimous decision found that naturally occurring DNA is a product of nature and not patent eligible merely because it has been isolated. “Laws of nature, natural phenomena, and abstract ideas … are basic tools of scientific and technological work” that lie beyond patent protection, wrote Justice Clarence Thomas on behalf of all justices. Justice Antonio Scalia did file a short concurrence stating that he cannot sign on to the discussion relating to the finer details of biology. http://www.supremecourt.gov/opinions/12pdf/12-398_8njq.pdf

However, the Court also ruled that cDNA is patent eligible because it is not naturally occurring. Some cDNA patents may not be patent eligible where the cDNA is indistinguishable from natural DNA. The Court expresses no opinion on whether cDNA is otherwise patentable.

“The restriction of research on these genes has violated time-honored principles of free exchange of information in the areas of scientific inquiry,” Dr. Kroft said.

Additionally as a result of the U.S. Supreme Court ruling, laboratories nationwide can provide more genetic testing and patient diagnosis by pathologists that will inevitably lead to new developments in genetic research. This allows for greater possibility for improved screening for breast and ovarian cancer. The earlier detection will improve patient outcomes, resulting in fewer deaths for patients. Now patients can obtain a second opinion, which Myriad Genetics has not allowed.

Genetic testing can be developed that screens multiple genes for certain conditions, giving patients and pathologists a better understanding of how genetic factors might affect diagnoses and treatment.

BRCA1 and BRCA2 are two of 23,000 genes in the human genome. Up to 2.5 percent of all women in the United States have BRCA1 or BRCA2 gene mutations, which results in a 50- to 90-percent lifetime risk for breast cancer and a 25- to 50-percent risk for ovarian cancer. This compares to an average women’s lifetime risk of 12.2 percent for breast cancer and 1.7 percent for ovarian cancer.

Now those restrictions are removed, and patients will reap the benefits.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10831810.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
2. New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury
3. U.S. Supreme Court Rejects Challenge to New Cigarette Labeling
4. Human Gene Patent Case Goes to Supreme Court
5. Cell Phone Radiation Lawsuit Update: ICEMS Position Paper Supports Italian Supreme Court Ruling on Cell Phones and Brain Tumors, Bernstein Liebhard LLP Reports
6. Supreme Court Ruling Sets Stage for Full Rollout of Health-Care Reform Law
7. Coral Calcium Company Announces New Offer Amidst Supreme Court Healthcare Decisions
8. Supreme Court Backs Much of Controversial Health Reform Law
9. Supreme Court Surprises in Citizens United Montana Case, Delays Order
10. America Awaits Supreme Courts Ruling on Health Care Reform
11. National Alliance For Hispanic Health Leads Diverse “Friends of the Court” in Support of NYC Policy to Reduce Sugary Drink Portion Size
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... of the Golden Bridge Awards® - for Risk Management Solution Innovations and Security ... Halo™ online platform released in 2017 and its DHS SAFETY Act-designated enterprise ...
(Date:8/22/2017)... Alpharetta, GA (PRWEB) , ... August 22, 2017 , ... ... across America, has awarded Zyclear Migraine Relief with the 2017 Women’s Choice Award. The ... as studies show that 3 out of 4 migraine sufferers are women. In a ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent ... these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year ... came in. Now, it's time to announce the winners of the sixth annual Photo Contest, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Glimpses Of ... understanding of the world. “Glimpses Of Light” is the creation of published author, J.M. ... life in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- AOTI Inc. announced today that its fully owned USA ... New York City Office in Yonkers, New York ... Oxygen (TWO 2 ) homecare therapy. This new East Coast location ... (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology: